Modulation of auditory deviance detection by acute nicotine is baseline and deviant dependent in healthy nonsmokers: A mismatch negativity study

Human Psychopharmacology

Volumn 29, Issue 5, 2014, Pages 446-458

  Knott, Verner ^a   Impey, Danielle ^a   Philippe, Tristan ^a   Smith, Dylan ^a   Choueiry, Joelle ^a   De La Salle, Sara ^a   Dort, Heather ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Auditory sensory memory; Event related potential; Mismatch negativity; Nicotine; Nicotinic acetylcholine receptors; Schizophrenia

Indexed keywords

NICOTINE; NICOTINE GUM; NICOTINIC AGENT; NICOTINIC RECEPTOR; PLACEBO; PSYCHOTROPIC AGENT;

ADOLESCENT; ARTICLE; AUDITORY DISCRIMINATION; AUDITORY MEMORY; CHEWING GUM; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; EVENT RELATED POTENTIAL; FRONTAL CORTEX; HUMAN; HUMAN EXPERIMENT; LATENT PERIOD; MALE; MISMATCH NEGATIVITY; NEUROTRANSMISSION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; SCHIZOPHRENIA; SENSORY MEMORY; SMOKING; TOBACCO USE; ADULT; AUDITORY STIMULATION; BRAIN; DRUG EFFECTS; ELECTROENCEPHALOGRAPHY; EVOKED RESPONSE; HEARING; PERCEPTIVE DISCRIMINATION; PHYSIOLOGY; YOUNG ADULT;

ACOUSTIC STIMULATION; ADOLESCENT; ADULT; AUDITORY PERCEPTION; BRAIN; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; HUMANS; MALE; NICOTINE; NICOTINIC AGONISTS; PSYCHOTROPIC DRUGS; SIGNAL DETECTION, PSYCHOLOGICAL; YOUNG ADULT;

EID: 84922663705     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2418     Document Type: Article

References (134)

1. Baldeweg T, Wong D, Stephan K. 2006. Nicotinic modulation of human auditory sensory memory: Evidence from mismatch negativity potentials. Int J Psychophysiol 59: 49-58.
2. Barch D, Mathalon D. 2011. Using brain imaging measures in studies of precognitive pharmacologic agents in schizophrenia: Psychometrics and quality assurance considerations. Biol Psychiatry 70: 13-18.
3. Barch D, Carter C, Arnsten A, et al. 2009. Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: Proceedings of the third CNTRICS meeting. Schizophr Bull 35: 109-114.
4. Barnett A, van der Pols JC, Dobson AJ. 2005. Regression to the mean: what it is and how to deal with it. Int J Epidemiol 34: 215-220.
5. Bazana P, Stelmack R. 2002. Intelligence and information processing during an auditory discrimination task with backward masking: an event-related potential analysis. bJ Pers Soc Psychol 83: 998-1008.
6. Beaver J, Long C, Cole D, et al. 2011. The effects of nicotine replacement on cognitive brain activity during smoking withdrawal studies with simultaneous fMRI/EEG. Neuropsychopharmacology 36: 1792-1800.
7. Bentley P, Driver J, Dolan, RJ. 2011. Cholinergic modulation of cognition: insights from human pharmacological functional neuroimaging. Prog Neurobiol 94(4): 360-388.
8. Butler P, Chen Y, Ford J, Geyer M, Silverstein S, Green M. 2012. Perceptual measurement in schizophrenia: Promising electrophysiology and neuroimaging paradigms from CNTRICS. Schizophr Bull 38: 81-91.
9. Carter C. 2005. Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia. Schizophr Bull 31: 810-815.
10. Carter C, Barch D. 2007. Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull 35: 1131-1137.
11. Carter C, Barch D, Bullmore E, et al. 2011. Cognitive neuroscience treatment research to improve cognition in schizophrenia II: Developing imaging biomarkers to enhance treatment development for schizophrenia and related disorder. Biol Psychiatry 20: 7-12.
12. Chatrian GE, Lettich E, Nelson PL. 1985. Ten percent electrode system for topographic studies of spontaneous and evoked EEG activity. Am J EEG Technol 25: 83-92.
13. Cho R, Ford J, Krystal J, et al. 2005. Functional neuroimaging and electrophysiology biomarkers for clinical trials for cognition in schizophrenia. Schizophr Bull 31: 865-869.
14. Cole D, Beckmann C, Long C, Matthews P, Durcan M, Beaver J. 2010. Nicotine replacement in abstinent smokers improves cognitive withdrawal symptoms with modulation of resting brain network dynamics. Neuroimage 52: 590-599.
15. Cropsey KL, Eldridge GD, Weaver MF, Villalobos GC, Stitzer ML. 2006. Expired carbon monoxide levels in self-reported smokers and non-smokers in prison. Nic Tob Res 8(5): 653-659.
16. Csomor P, Stadler R, Feldon J, Yee B, Geyer M, Vollenweider F. 2008. Haloperidol differentially modulates prepulse inhibition and P50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology 33: 497-512.
17. D'Souza M, Markou A. 2012. Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits. Neuropharma Col 62: 1564-1573.
18. D'Souza D, Esterlis I, Carbuto M, et al. 2012. Lower β2-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am J Psychiatry 169: 326-334.
19. Dani J, Bertrand D. 2007. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Ann Rev Pharmacol Toxicol 47: 699-729.
20. Dickerson F, Stallings C, Origoni A, et al . 2013. Cigarette smoking among persons with schizophrenia or bipolar disorder in routine-clinical settings, 1999-2011. Psychiatr Serv 64: 44-50.
21. Dos Santos C, Granon S. 2012. Prefrontal neuromodulation by nicotinic receptors for cognitive processes. Psychopharmacology (Berl) 22: 1-18.
22. Dulude L, Labelle A, Knott, V. 2010. Acute nicotine-alteration of sensory memory impairment in smokers with schizophrenia. J Clin Psychopharmacol 30: 541-548.
23. Dunbar G, Boeijinga H, Demazieres A, et al. 2007. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berl) 191: 919-929.
24. Ettinger U, Williams S, Patal D, et al. 2009. Effects of acute nicotine on brain function in healthy smokers and non-smokers: estimation of inter-individual response heterogeneity. Neuroimage 45: 549-561.
25. First M, Spitzer R, Williams J, Gibbon M. 1995. Structured clinical interview for DSM-IV - Non-Patient Edition (SCID-NP, Version 1.0). American Psychiatric, Washington, DC.
26. Fisher D, Grant B, Smith D, Borracci G, Labelle A, Knott V. 2012. Nicotine and the hallucinating brain: Affects on mismatch negativity (MMN) in schizophrenia. Psychiatry Res 196: 181-187.
27. Fisher D, Scott T, Shah D, Prise S, Thompson M, Knott V. 2010. Light up and see: Enhancement of the visual mismatch negativity (vMMN) by nicotine. Brain Res 1313: 162-171.
28. Flores-Hernandez J, Salgado H, De la Rossa V, et al. 2009. Cholinergic direct inhibition of M-methyl-D-aspartate receptor-mediated currents in the rat neurocortex. Synapse 63: 308-318.
29. Garrido MI, Kilner JM, Stephan KE, Friston KJ. 2009. The mismatch negativity: a review of underlying mechanisms. Clin Neurophysiol 120(3): 453-463.
30. NIMH Genetics Initiative. 1992. Family interview for genetic studies. Rockville, MD: National Institute of Mental Health.
31. Gilbert D, Gilbert B. 1995. Personality psychopathology, and nicotine response as mediations of the genetics of smoking. Behav Genet 2f: 133-147.
32. Goff DC, Henderson DC, Amico E. 1992. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am J Psychiatry 149: 1189-1194.
33. Gold J. 2004. Cognitive deficits as treatment targets in schizophrenia. Schizophr Res 72: 21-28.
34. Gratton G, Coles MG, Donchin E. 1983. A new method for off-line removal of ocular artifact. EEG Clin Neurophysiol 55(4): 468-484.
35. Green M. 2007. Stimulating the development of drug treatments to improve cognition in schizophrenia. Ann Rev Clin Psychol 3: 159-180.
36. Green M, Butler P, Chen Y, et al. 2009. Perception measurement in clinical trials of schizophrenia: Promising paradigms from CNTRICS. Schizophr Bull 35: 163-181.
37. Hall M, Schulze K, Rijsdijk F, et al . 2006. Heritability and reliability of P300, P50 and duration mismatch negativity. Behav Genet 36: 845-857.
38. Harkrider A, Hedrick M. 2005. Acute effect of nicotine on auditory gating in smokers and non-smokers. Hear Res 202: 114-128.
39. Heishman S, Kleykamp B, Singleton E. 2010. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology (Berl) 210: 453-469.
40. Heishman S, Taylor R, Henningfield J. 1994. Nicotine and smoking: a review of the effects on human performance. Exp Clin Psychopharmacol 2: 345-395.
41. Holstein D, Csomor P, Geyer M, et al. 2011. The effects of sertindole on sensory gating, sensorimotor gating, and cognition in healthy volunteers. J Psychopharmacol 25: 1600-1613.
42. Hong LE, Thaker GK, McMahon RP, et al. 2011. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 68(12): 1195.
43. Horton J, Millar A, Labelle A, Knott V. 2011. MMN responsivity to manipulations of frequency and duration deviants in chronic, clozapine-treated schizophrenia patients. Schizophr Res 126: 202-218.
44. Hukkanen J, Jacob P, Benowitz NL. 2005. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57(1): 79-115.
45. Ichikawa J, Dai J, O'Laughlin I, Fowler W, Meltzer H. 2002. Atypical but not typical antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacol 26: 325-339.
46. Inami R, Kirino E, Inoue AH. 2005. Transdermal nicotine administration enhances automatic auditory processing reflected by mismatch negativity. Pharmacol Biochem Behav 80: 453-461.
47. Inami R, Kirino E, Inoue R, Suzuki T, Arai H. 2007. Nicotine effects on mismatch negativity in nonsmoking schizophrenic patients. Neuropsychobiol 56: 64-72.
48. Javitt D. 2000. Intracortical mechanisms of mismatch negativity dysfunction in schizophrenia. Audiol Neuro Tol 5: 207-215.
49. Javitt D. 2009. Sensory processing in schizophrenia. Neither simple nor intact. Schizophr Bull 35: 1059-1064.
50. Javitt D, Steinschneider M, Schroeder C, Arezzo J. 1996. Role of cortical N-methyl-D-aspartate in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc Natl Acad Sci U S A 93: 11962-11967.
51. Ji W, Suga N. 2008. Tone-specific and nonspecific plasticity of the auditory cortex elicited by pseudoconditioning: rule of acetylcholine receptors and the somatosensory cortex. J Neurophysiol 100: 1384-1396.
52. Kathmann N, Frodl-Bauch T, Hegerl V. 1999. Stability of the mismatch negativity under different stimulus and attention conditions. Clin Neurophysiol 110: 317-323.
53. Kern R, Nuechterlein K, Green M, et al. 2008. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry 165: 214-220.
54. Kiang M, Light G, Prugh J, Coulson S, Bralb D, Kutas M. 2007. Cognitive, neurophysiological and functional correlates of proverb interpretation abnormalities in schizophrenia. J Int Neuropsychol Soc 13: 653-663.
55. Knott V, Bolton K, Heenan A, Shah D, Fisher D, Villeneuve C. 2009. Effects of acute nicotine on event-related potential and performance indices of auditory distraction in nonsmokers. Nic and Tob Res 11: 519-530.
56. Knott V, de la Salle S, Smith D, et al. 2013. Baseline dependency of nicotine's sensory gating actions: similarities and differences in low, medium and high P50 suppressors. J Psychopharmacol 27: 790-800.
57. Knott V, Fisher D, Millar A. 2010. Differential effects of nicotine on P50 amplitude, its gating and their neural sources in low and high suppressions. Neurosci 170: 816-826.
58. Knott V, Heenan A, Shah D, Bolton K, Fisher D, Villeneuve C. 2011. Electrophysiological evidence of nicotine's distractor-filtering properties in non-smokers. J Psychopharmacol 25: 239-248.
59. Knott V, Scherling C, Blais C, et al. 2006. Acute nicotine fails to alter event-related potential or behavioural performance indices of auditory distraction in cigarette smokers. Nic and Tob Res 8: 263-273.
60. Knott V, Shah D, Millar A, et al. 2012. Nicotine, auditory sensory memory, and sustained attention in a human ketamine model of schizophrenia: Moderating influence of an hallucinatory trait. Front Pharmacol 3: 172.
61. Kucinski A, Stachowiak M, Wersinger S, Lippiello P, Bencherif M. 2011. Alpha 7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia. Curr Pharm Biotechnol 12: 437-448.
62. Kumari V, Postma P. 2005. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev 29: 1021-1034.
63. Kupferschmidt D, Funk D, Erb S, Lo A. 2010. Age-related effects of acute nicotine on behavioural and neuronal measures of anxiety. Behav Brain Bes 213: 289-292.
64. Leiser SC, Bowlby MR, Comery TA, Dunlop J. 2009. A cog in cognition: how the α7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacology Ther 122(3): 302-311.
65. Levin E. 2002. Nicotinic receptor subtypes and cognitive function. J Neurobiol 53: 633-640.
66. Levin E, Simon B. 1998. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 138: 217-230.
67. Levin E, McClernon F, Rezvani A. 2006. Nicotinic effects on cognitive function: behavioural characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 184: 523-539.
68. Levy R, Aoki C. 2002. α7 nicotinic acetylcholine receptors occur at post-synaptic densities of AMPA receptor-positive- and negative-excitatory synapses of rat sensory cortex. J Neurosci 22: 5001-5015.
69. Li M, Mead A, Bevins R. 2009. Individual differences in response to nicotine: tracking changes from adolescence to adulthood. Acta Pharmacol Sin 30: 868-878.
70. Liang K, Poytress B, Weinberger M, Metherate R. 2008. Nicotinic modulation of tone-evoked responses in auditory cortex reflects the strength of prior learning. Neurobiol Learn Mem 90: 138-146.
71. Lieberman JA, Dunbar G, Segreti AC, et al. 2013. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 38(6): 968-975.
72. Light G, Braff D. 2005. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry 62: 127-136.
73. Light G, Swendlow M, Braff D. 2007. Preattentive sensory processing as indexed by the MMN and P38 brain responses associated with cognitive and psychosocial functioning in healthy adults. J Cogn Neurosci 19: 1624-1632.
74. Mackowick KM, Barr MS, Wing VC, Rabin RA, Ouellet-Plamondon C, George TP. 2013. Neurocognitive Endophenotypes in Schizophrenia: Modulation by Nicotinic Receptor Systems. Prog Neuro-Psychopharm Biol Psychiatry 52: 79-85.
75. Mansvelder H, Mertz M, Role L. 2009. Nicotinic modulation of synaptic transmission and plasticity in cortico-limbic circuits. Semin Cell Dev Biol 20: 432-440.
76. Mansvelder H, Van Aerde K, Couey J, Brussaard A. 2006. Nicotinic modulation of neuronal networks: from receptors to cognition. Psychopharmacol 184: 292-305.
77. Marder S, Fenton W. 2004. Measurement and treatment research to improve cognition in schizophrenica: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 72: 5-9.
78. Martin L, Davalos D, Kisley M. 2009. Nicotine enhances automatic temporal processing as measured by the mismatch negativity waveform. Nic Tob Res 11: 698-706.
79. Matsubayashi J, Kawakubo Y, Suga M, et al. 2008. The influence of gender and personality traits on individual difference in auditory mismatch: A magnetoencephalographic (MMNm) study. Brain Res 1236: 159-165.
80. McEvoy JP, Freudenreich O, Wilson WH. 1999. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 46: 125-129.
81. Metherate R. 2004. Nicotinic acetylcholine receptors in sensory cortex. Learn Mem 11: 50-59.
82. Metherate R, Hsieh C. 2003. Regulation of glutamate synapses by nicotinic acetylcholine receptors in auditory cortex. Neurobiol Learn Mem 80: 285-290.
83. Mexal S, Berger R, Logel J, Ross R, Freedman R, Leonard S. 2010. Differential regulation of alpha7 nicotinic receptorgene (CHRNA7) expression in schizophrenic smokers. J Mol Neurosci 40: 185-195.
84. Morisano D, Wing V, Sacco K, Arenovich T, George T. 2013. Effects of tobacco smoking on neuropsychological function in schizophrenia in comparison to other psychiatric disorders and non-psychiatric controls. AMJ Addict 22: 46-53.
85. Näätanen R, Kähkonën S. 2008. Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMMm: a review. Int J Neuropsychopharmacol 12: 125-135.
86. Näätänen R, Kujala T, Escera I, et al . 2012. The mismatch negativity (MMN) - unique window to disturbed central auditory processing in aging and different clinical conditions. Clin Neurophysiol 123: 424-458.
87. Näätänen R, Kujala T, Winkler I. 2011. Auditory processing that leads to conscious perception: a unique window to central auditory processing opened by the mismatch negativity and related responses. Psychophysiology 48: 4-12.
88. Näätänen R, Pakarinen S, Rinne T, Takegata R. 2004. The mismatch negativity (MMS): towards the optimal paradigm. Clin Neurophysiol 215: 140-144.
89. Nagai T, Tada M, Kirihara K, Araki T, Jinde S, Kasai K. 2013. Mismatch negativity as a "translatable" brain marker toward early intervention for psychosis: a review. Front Psychiatry 4: 115.
90. Nasrallah H, Tandon R, Keshaven M. 2011. Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment. Epidemiol Psychiatr 20: 317-327.
91. Newhouse P, Potter A, Singh A. 2004. Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol 4: 36-46.
92. Nuechterlein K, Barch D, Gold J, Goldberg T, Green M, Heaton R. 2004. Identification of separate cognitive factors in schizophrenia. Schizophr Res 72: 29-39.
93. Nuechterlein K, Green M, Kern R, et al. 2008. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 165: 203-213.
94. Oldfield RC. 1971. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9(1): 97-113.
95. Olincy A, Freedman R. 2012. Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the alpha7 nicotinic receptor. Handb Exp Pharmacol 213: 211-232.
96. Olincy D, Young R, Freedman R. 1997. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry 42: 1-5.
97. Opitz B, Rinne T, Mecklinger A, von Cramon DY, Schröger E. 2002. Differential contribution of frontal and temporal cortices to auditory change detection: fMRI and ERP results. Neuroimage 15: 167-74.
98. Perkins K. 1995. Individual variability in response to nicotine. Behav Genet 25: 119-132.
99. Perkins K. 1999. Baseline-dependency of nicotine affects: a review. Behav Pharmacol 10: 595-615.
100. Perkins K. 2009. Sex differences in nicotine reinforcement and reward: influences on the persistence of tobacco smoking. Nebr Symp Motiv 55: 143-169.
101. Petrovsky N, Ettinger U, Quednow B, et al. 2012. Nicotine differentially modulates antisaccade performance in healthy male non-smoking volunteers stratified for low and high accuracy. Psychopharmacol 221: 27-38.
102. Poltavski D, Petros T. 2005. Effects of transdermal nicotine on prose memory and attention in smokers and nonsmokers. Physiol Behav 83: 833-843.
103. Poorthuis R, Goriunova N, Covey J, Mansvelder H. 2009. Nicotinic actions on neuronal networks for cognition: General principles and long-term consequences. Biochem Pharmacol 78: 668-676.
104. Qiao Z, Yu Y, Wang L, et al. 2013. Impaired pre-attentive change detection in major depressive disorder patients revealed by auditory mismatch negativity. Psychiatry Res: Neuroimaging 211: 78-84.
105. Radek R, Kohlhaas K, Reuter L, Mohler E. 2010. Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists. Curr Pharm Des 16: 309-322.
106. Rasser P, Schall U, Todd J, et al. 2011. Gray matter deficits, mismatch negativity and outcomes in schizophrenia. Schizophr Bull 37: 131-140.
107. Rinne T, Alho K, Ilmoniemi RJ, Virtanen J, Näätänen R. 2000. Separate time behaviors of the temporal and frontal mismatch negativity sources. Neuroimage 12(1): 14-9.
108. Ruzzoli M, Pirulli C, Brignani D, Maioli C, Miniussi C. 2012. Sensory memory during physiological aging indexed by mismatch negativity (MMN). Neurobiol Aging 33: e21-e30.
109. Sabri M, Campbell KB 2002. The effects of digital filtering on mismatch negativity in wakefulness and slow-wave sleep. J Sleep Res 11: 123-127.
110. Salisbury D, Kuroki N, Kasai K, et al. 2007. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch Gen Psychiatry 64: 521-529.
111. Sarter M, Parikh V, Howe V. 2009. nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms. Biochem Pharmacol 78: 658-667.
112. Scherg M, Vajsar J, Picton T. 1989. A source analysis of the late human auditory evoked potentials. J Cogn Neurosci 1: 336-355.
113. Sherwood N. 1993. Effects of nicotine on human performance. Hum Psychopharmacol 8: 155-184.
114. Shinozaki M, Yabe H, Sato Y, et al. 2002. The difference in mismatch negativity between the acute and post-acute phase of schizophrenia. Biol Psychol 59: 105-119.
115. Soto G, Kopell M, Sen K. 2006. Network architecture, receptive fields, and neuromodulation: computational and functional implications of cholinergic modulation in primary auditory cortex. J Neurophyscol 96: 2972-2783.
116. Strand J, Nyback H. 2005. Tobacco use in schizophrenia: study of cotinine concentration in the saliva of patients and controls. Eur Psychiatry 20: 50-54.
117. Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M. 2012. Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat prefrontal cortex and primary cultural astrocytes. Br J Pharmacol 165: 1543-1555.
118. Tandon R, Nasrallah H, Keshaven M. 2010. Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present and future. Schizophr Res 20: 1-23.
119. Tata M, Ward L. 2005. Early phase of spatial mismatch negativity is localized to a posterior "where" auditory pathway. Exp Brain Res 167: 481-486.
120. Tervaniemi M, Lehtokoski A, Sinkkonen J, Virtanen J, Ilmoniemi R, Naatanen R. 1999. Test-retest reliability of mismatch negativity for duration, frequency and intensity changes. Clin Neurophysiol 110: 1388-1393.
121. Thaker G. 2008. Neurophysiological endophenotypes across bipolar and schizophrenic psychosis. Schizophr Bull 34: 760-773.
122. Tikhonravov D, Neuvonen T, Pertovaara A, et al. 2008. Effects of an NMDA receptor antagonist MK-801 on an MMN-like response in anesthetized rats. Brain Res 1203: 97-102.
123. Todd J, Harms L, Schall U, Mitchie P. 2013. Mismatch negativity: Translating the potential. Front Psychiatry 4: 1-22.
124. Todd J, Mitchie P, Schall U, Karayanidis F, Yabe H, Naatanen R. 2008. Deviants matter: Duration, frequency, and intensity deviants reveal different patterns of mismatch negativity reduction in early and late schizophrenia. Biol Psychiatry 63: 58-64.
125. Toledano A, Alvarez M, Toledano-Diaz A. 2010. Diversity and variability of the effects of nicotine on different cortical regions of the brain - therapeutic and toxicological implications. Cent Nerv Syst Agents Med Chem 10: 180-206.
126. Turetsky B, Bilker W, Siegel S, et al. 2009. Profile of auditory information processing deficits in schizophrenia. Psychiatry Res 165: 27-37.
127. Umbricht D, Krljes S. 2005. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 76: 1-23.
128. Umbricht D, Bates J, Lieberman J, Kune J, Javitt D. 2006. Electrophysiological indices of automatic and controlled auditory information processing in first episode, recent onset and chronic schizophrenia. Biol Psychiatry 59: 762-772.
129. Umbricht D, Schmid L, Koller R, Vollenweider F, Hill D, Javitt D. 2000. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers. Arch Gen Psychiatry 57: 1139-1197.
130. Vollenweider F, Barro M, Csomor P, Feldon J. 2006. Clozapine enhances prepulse inhibition in healthy humans with low but not with high prepulse inhibition levels. Biol Psychiatry 80: 597-603.
131. Wallace TL, Bertrand D. 2013. Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex. Biochem Pharmacol 85(12): 1713-20.
132. Winterer G, Gallinat J, Brinkmeyer J, et al. 2013. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology 64: 197-204.
133. Wynn J, Sugar C, Horan W, Kern R, Green M. 2010. Mismatch negativity, social cognition, and functioning in schizophrenia patients. Biol Psychiatry 67: 940-947.
134. Yamamoto R, Rohan M, Goletiani N, et al. 2013. Nicotine related brain activity: the influence of smoking history and blood nicotine levels, an exploratory study. Drug Alcohol Depend 129: 137-144.